Literature DB >> 18811590

Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity.

Troii Hall1, Joseph W Leone, Joseph F Wiese, David W Griggs, Lyle E Pegg, Adele M Pauley, Alfredo G Tomasselli, Marc D Zack.   

Abstract

Members of the ADAM (a disintegrin and metalloproteinase) family of proteins possess a multidomain architecture which permits functionalities as adhesion molecules, signalling intermediates and proteolytic enzymes. ADAM8 is found on immune cells and is induced by multiple pro-inflammatory stimuli suggesting a role in inflammation. Here we describe an activation mechanism for recombinant human ADAM8 that is independent from classical PC (pro-protein convertase)-mediated activation. N-terminal sequencing revealed that, unlike other ADAMs, ADAM8 undergoes pre-processing at Glu(158), which fractures the Pro (pro-segment)-domain before terminal activation takes place to remove the putative cysteine switch (Cys(167)). ADAM8 lacking the DIS (disintegrin) and/or CR (cysteine-rich) and EGF (epidermal growth factor) domains displayed impaired ability to complete this event. Thus pre-processing of the Pro-domain is co-ordinated by DIS and CR/EGF domains. Furthermore, by placing an EK (enterokinase) recognition motif between the Pro- and catalytic domains of multiple constructs, we were able to artificially remove the pro-segment prior to pre-processing. In the absence of pre-processing of the Pro-domain a marked decrease in specific activity was observed with the autoactivated enzyme, suggesting that the Pro-domain continued to associate and inhibit active enzyme. Thus, pre-processing of the Pro-domain of human ADAM8 is important for enzyme maturation by preventing re-association of the pro-segment with the catalytic domain. Given the observed necessity of DIS and CR/EGF for pre-processing, we conclude that these domains are crucial for the proper activation and maturation of human ADAM8.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18811590     DOI: 10.1042/BSR20080145

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  10 in total

1.  Structure of human ADAM-8 catalytic domain complexed with batimastat.

Authors:  Troii Hall; Huey Sheng Shieh; Jacqueline E Day; Nicole Caspers; Jill E Chrencik; Jennifer M Williams; Lyle E Pegg; Adele M Pauley; Andrea F Moon; Joseph M Krahn; David H Fischer; James R Kiefer; Alfredo G Tomasselli; Marc D Zack
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-05-22

2.  The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site.

Authors:  Eitan Wong; Thorsten Maretzky; Yoav Peleg; Carl P Blobel; Irit Sagi
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

3.  IL-5-stimulated eosinophils adherent to periostin undergo stereotypic morphological changes and ADAM8-dependent migration.

Authors:  M W Johansson; M Khanna; V Bortnov; D S Annis; C L Nguyen; D F Mosher
Journal:  Clin Exp Allergy       Date:  2017-05-05       Impact factor: 5.018

Review 4.  ADAM8: a new therapeutic target for asthma.

Authors:  Martin D Knolle; Caroline A Owen
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

5.  Fibronectin fragments and the cleaving enzyme ADAM-8 in the degenerative human intervertebral disc.

Authors:  Nancy Ruel; Dessislava Z Markova; Sherrill L Adams; Carla Scanzello; Gabriella Cs-Szabo; David Gerard; Peng Shi; D Greg Anderson; Marc Zack; Howard S An; Di Chen; Yejia Zhang
Journal:  Spine (Phila Pa 1976)       Date:  2014-07-15       Impact factor: 3.468

6.  Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8).

Authors:  M D Zack; M A Melton; J L Stock; C E Storer; R A Barve; J C Minnerly; D J Weiss; J A Stejskal; M D Tortorella; J R Turk; K M Shevlin; A-M Malfait
Journal:  Clin Exp Immunol       Date:  2009-08-06       Impact factor: 4.330

Review 7.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

8.  Elevated inflammatory gene expression in intervertebral disc tissues in mice with ADAM8 inactivated.

Authors:  Yejia Zhang; Zuozhen Tian; David Gerard; Lutian Yao; Frances S Shofer; Gabriella Cs-Szabo; Ling Qin; Maurizio Pacifici; Motomi Enomoto-Iwamoto
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.996

9.  ADAM8 signaling drives neutrophil migration and ARDS severity.

Authors:  Catharina Conrad; Daniela Yildiz; Simon J Cleary; Andreas Margraf; Lena Cook; Uwe Schlomann; Barry Panaretou; Jessica L Bowser; Harry Karmouty-Quintana; Jiwen Li; Nathaniel K Berg; Samuel C Martin; Ahmad Aljohmani; S Farshid Moussavi-Harami; Kristin M Wang; Jennifer J Tian; Mélia Magnen; Colin Valet; Longhui Qiu; Jonathan P Singer; Holger K Eltzschig; Wilhelm Bertrams; Susanne Herold; Norbert Suttorp; Bernd Schmeck; Zachary T Ball; Alexander Zarbock; Mark R Looney; Jörg W Bartsch
Journal:  JCI Insight       Date:  2022-02-08

Review 10.  ADAM and ADAMTS family proteins and their role in the colorectal cancer etiopathogenesis.

Authors:  Leszczynski Przemyslaw; Hendrich Andrzej Boguslaw; Szmida Elzbieta; Sasiadek Maria Malgorzata
Journal:  BMB Rep       Date:  2013-03       Impact factor: 4.778

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.